Roche Holding AG





Market Closed - Swiss Exchange 11:30:23 2024-02-23 am EST 5-day change 1st Jan Change
232.4 CHF +1.55% Intraday chart for Roche Holding AG +1.84% -4.95%
This article is reserved for subscribers
To unlock the article, SUBSCRIBE!
Already a customer? Log In
Drugs, fashion and chips - the STOXX 600's 'Magnificent 4' RE
ROCHE HOLDINGS AG : UBS remains Neutral ZD
ROCHE HOLDINGS AG : JP Morgan gives a Sell rating ZD
Investors warm to Swiss stocks, weakening franc breaks the ice RE
Immune-Onc Therapeutics, Inc. Announces Phase 1b/2 Clinical Trial Collaboration with Roche CI
ROCHE HOLDINGS AG : Berenberg gives a Neutral rating ZD
Roche: extended collaboration with Denmark's BioPorto CF
BioPorto Expands Global Distribution Partnership with Roche Diagnostics MT
Swiss Market Index Closes in the Green on Healthcare Stocks Boost MT
EMEA Morning Briefing : Stocks Seen Lower at Start of Week DJ
News Highlights : Top Company News of the Day - Friday at 7 PM ET DJ
News Highlights : Top Company News of the Day - Friday at 5 PM ET DJ
News Highlights : Top Company News of the Day - Friday at 3 PM ET DJ
News Highlights : Top Company News of the Day - Friday at 1 PM ET DJ
Roche Gets U.S. Approval for Food Allergy Drug DJ
Roche’s Food Allergy Drug Xolair Obtains US FDA Approval MT
Novartis, Roche's Food Allergies Treatment Xolair Gets FDA Approval DJ
Roche: FDA approves allergy treatment CF
Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies CI
Redburn Atlantic Lowers Price Target on Roche, Maintains Buy Recommendation MT
Freenome Holdings, Inc. announced that it has received $254 million in funding from a group of investors CI
Schroders Capital Global receives Carmot sale distribution AN
Roche: new AI collaboration with PathAI CF
Schroders Capital Global Receives $6 Million from Carmot Therapeutics Sale MT
Roche Partners With AI Firm to Develop Algorithms in Companion Diagnostics DJ
Chart Roche Holding AG
More charts
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
232.4 CHF
Average target price
285.2 CHF
Spread / Average Target
1st Jan change Capi.
-4.95% 209 B $
+31.63% 693 B $
+21.62% 552 B $
+3.18% 386 B $
+18.66% 328 B $
+14.89% 312 B $
+7.97% 210 B $
-3.58% 197 B $
-3.39% 156 B $
+0.39% 153 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Roche Holding AG - Swiss Exchange
  4. News Roche Holding AG
  5. Roche Holding : Roche dips a toe in the lucrative anti-obesity market
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance